Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17344792 | 0.75 | GAA (0.50) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL17344768 | 0.75 | ALOX15 (0.32) | — | |
| SCHEMBL17349174 | 0.69 | GAA (0.46) | GAANPSR1ALOX5MEN1MAPT | |
| SCHEMBL17344788 | 0.68 | NOS2 (0.33) | — | |
| SCHEMBL5672804 | 0.68 | ALOX5 (0.50) | GAANPSR1ALOX5MEN1MAPT | |
| SCHEMBL30549 | 0.62 | — | — | |
| SCHEMBL28141260 | 0.62 | GAA (0.60) | GAANPSR1ALOX5MEN1MAPT | |
| SCHEMBL16558283 | 0.61 | GAA (0.40) | GAANPSR1ALOX5MAPT | |
| Hydrochloric Acid SCHEMBL31003509 | 0.60 | GAA (0.41) | GAANPSR1ALOX5MEN1MAPT | |
| SCHEMBL10670210 | 0.60 | ALOX15 (0.39) | GAANPSR1ALOX5MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | GAA 2728/4885NPSR1 3491/4885ALOX5 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.